Effect of a fixed-dose opioid agonist/antagonist on constipation in patients on long-term opioids for non-malignant pain unable to tolerate laxatives

Pain Physician

Volumn 17, Issue 5, 2014, Pages 415-424

  Mehta, Vivek ^a   Alaward, Sami ^a   Kuravinakop, Sanjay ^a   Nikolic, Serge ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Audit; Laxatives; Naloxone; Non malignant pain; Opioid; Opioid induced constipation; Oxycodone

Indexed keywords

LAXATIVE; NALOXONE PLUS OXYCODONE; OPIATE; DRUG COMBINATION; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; OXYCODONE;

ADULT; AGED; ARTICLE; BOWEL FUNCTION INDEX; BRIEF PAIN INVENTORY; CHRONIC PAIN; CLINICAL ARTICLE; CONSTIPATION; DEFECATION; DIARRHEA; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTESTINE FUNCTION; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; PATIENT ASSESSMENT OF CONSTIPATION QUALITY OF LIFE QUESTIONNAIRE; QUALITY OF LIFE; TREATMENT OUTCOME; CHEMICALLY INDUCED; DRUG COMBINATION; MIDDLE AGED;

ADULT; ANALGESICS, OPIOID; CHRONIC PAIN; CONSTIPATION; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OXYCODONE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84907299302     PISSN: 15333159     EISSN: 21501149     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Whitten CE, Evans CM, Cristobal K. Pain management doesn’t have to be a pain: Working and communicating effectively with patients who have chronic pain. Permanente J 2005; 9:41-48
2. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10:287-333
3. Donaldson, L. On the State of Public Health: Annual Report of the Chief Medical Officer. London: Department of Health; 2009 pp 33-39
4. The British Pain Society. Opioids for persistent pain: Good practice. January 2010
5. Zautra AJ, Smith BW. Impact of controlled- release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clin J Pain 2005; 21:471-477
6. Markenson JA, Croft J, Zhang PG, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled- release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005; 21:524-534
7. Hale ME, Fleischmann R, Salzman R, Wild J, Iwan T, Swanton RE, Kaiko RF, Lacouture PG. Efficacy and safety of controlled-release versus immediaterelease oxycodone: Randomized, double- blind evaluation in patients with chronic back pain. Clin J Pain 1999; 15:179-183
8. Kurz A, Sessler DI. Opioid-induced bowel dysfunction. Pathophysiology and potential new therapies. Drugs 2003; 63:649-671
9. Pappagallo M. Incidence, prevalence, and management of opioid induced bowel dysfunction. Am J Surg 2001; 182:11S-18S.
10. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: Prevalence, pathophysiology and burden. Int J Clin Pract 2007; 61:1181-1187
11. Yaun C-S, Pappagallo M. Handbook of opioid bowel syndrome. In: Yaun C-S (ed). Haworth Medical Press, New York, 2005, pp 1-2
12. Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, Troy Ferrarons J, Bosse B, Krain B, Nichols T, Kremers W, and Reimer K. Fixed-ratio combination oxycodone/ naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008; 24:3503-3512
13. Sandner-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W, Sevick P, Hakl M, Hrib R, Uhl R, Dürr H, Reimer K. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010; 64:763-774
14. Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, Bond S, Kremers W, Nichols T, Krain B, Reimer K. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: A randomised controlled trial. Expert Opin Pharmacother 2009; 10:531-543
15. Napp Pharmaceuticals Limited. Targinact tablets Summary of Product Characteristics: www.medicines.org.uk/emc/
16. Meissner W, Leyendecker P, Mueller- Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K. A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioidinduced constipation. Eur J Pain 2009; 13:56-64
17. Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Palaniappan K, Chruch A, Limb M, Connor A. Naloxone as part of a prolonged release oxycodone/ naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs 2011; 427-439
18. Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R, Reimer K. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther 2008; 30:2051-2068
19. Löwenstein O, Leyendecker P, Lux EA, Blagden M, Simpson KH, Hopp M, Bosse B, Reimer K. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: Results of a prospectively designed pooled analysis of two randomized double-blind clinical trials. BMC Clin Pharmacol 2010; 10:12
20. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A ramdomized, double-blind, activecontrolled, double-dummy, parallelgroup study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012; 26:50-60
21. Harris SC, Perrino PJ, Shram M, Bartlett C, Colucci SV, Wang Y. Abuse potential of oxycodone/naloxone (OXN) tablets administered intranasally in non-dependent recreational drug users with moderate opioid experience. PAINWeek, Las Vegas, USA, Apr 4 –7, 2013
22. Colucci SV, Perrino PJ, Shram M, Bartlett C, Wang Y, Harris CS. Abuse potential of oxycodone/naloxone solution administered intravenously in non-dependent recreational drug users with moderate opioid experience. PAINWeek, Las Vegas, USA, Apr 4 –7, 2013
23. Wang Y, Perrino PJ, Schoedel K, Geoffroy P, Colucci SV, Harris SC. Abuse potential of chewed or intact oxycodone/ naloxone (OXN) tablets in methadonestabilized, opioid-dependent subjects when administered orally. PAINWeek, Las Vegas, USA, Apr 4 –7, 2013
24. Perrino PJ, Colucci SV, Shram M, Bartlett C, Sellers EM, Wang Y, Harris SC. Relative attractiveness of oxycodone/ naloxone (OXN): Comparative assessment of tampering potential and recreational drug user preferences for different opioid formulations. PAINWeek, Las Vegas, USA, Apr 4 –7, 2013
25. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005; 40:540-551
26. Rentz AM, van Hanswijck de Jonge P, Leyendecker P, Hopp M. Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries. Curr Med Res Opin 2011; 27:35-44
27. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-in duced constipation. J Med Econ 2009; 12:371-383
28. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004; 20:309-318.